The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer
Official Title: A Phase II Clinical Trial of Bevacizumab Plus eRlotinIb in patientS With Advanced Cancer Having Genetic Alterations in Krebs Cycle (BRISK, KCSG AL22-16)
Study ID: NCT05904457
Brief Summary: A national, prospective, multi-center, open-label, single arm phase II trial investigating the efficacy and safety of bevacizumab plus erlotinib in patients with advanced cancers which harbors genomic alterations in Krebs cycle
Detailed Description: The BRISK study will recruit patients with locally advanced or metastatic solid tumor harboring the genomic alterations in Krebs cycle (e.g. fumarate hydratase, isocitrate dehydrogenase, succinate dehydrogenase) who had disease progression on standard systemic treatment and/or has no standard treatment option, and investigate the efficacy and safety of bevacizumab plus erlotinib.
Minimum Age: 19 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Chungnam National University Hospital, Daejeon, Chungcheongnam-do, Korea, Republic of
Cha University Bundang Medical Center, Seongnam, Gyeonggi-do, Korea, Republic of
Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of
Gyeongsang National University Hospital, Jinju, Gyeongsangnam-do, Korea, Republic of
Gachon University Gil Medical Center, Incheon, , Korea, Republic of
Korea University Anam Hospital, Seoul, , Korea, Republic of
Yonsei Cancer Hospital, Seoul, , Korea, Republic of
Asan Medical Center, Seoul, , Korea, Republic of
The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, , Korea, Republic of
Ulsan University Hospital, Ulsan, , Korea, Republic of